Double-Dose Hepatitis B Revaccination in Nonresponsive HIV-Infected Adolescents
There is no consensus regarding a best dosing regimen of hepatitis B virus vaccine (HBVV) for non-responsive HIV-infected individuals. Double-dose of hepatitis B vaccine (DDHBVV) could enhance immunogenicity to HBVV in non-responsive HIV-infected adults. We assessed the immunogenicity of DDHBVV in H...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2013-05-01
|
| Series: | Journal of the International Association of Providers of AIDS Care |
| Online Access: | https://doi.org/10.1177/1545109712473651 |
| _version_ | 1818385674729947136 |
|---|---|
| author | Torsak Bunupuradah MD Jintanat Ananworanich MD, PhD Thanyawee Puthanakit MD |
| author_facet | Torsak Bunupuradah MD Jintanat Ananworanich MD, PhD Thanyawee Puthanakit MD |
| author_sort | Torsak Bunupuradah MD |
| collection | DOAJ |
| description | There is no consensus regarding a best dosing regimen of hepatitis B virus vaccine (HBVV) for non-responsive HIV-infected individuals. Double-dose of hepatitis B vaccine (DDHBVV) could enhance immunogenicity to HBVV in non-responsive HIV-infected adults. We assessed the immunogenicity of DDHBVV in HIV-infected adolescents who failed to respond to standard HBVV revaccination. HIV-infected adolescents with current CD4 ≥ 200 cells/mm 3 and no protective antibody concentration of hepatitis B surface antibodies (antiHBs) after HBVV revaccination received DDHBVV, at months 0, 1, 2. The HBVV doses were 20 microgram per dose for adolescents aged < 18 years and 40 microgram per dose for adolescents aged ≥ 18 years. AntiHBs titers were measured at 1, 2, 3 months after first DDHBVV. AntiHBs ≥ 10 mIU/ml was considered protective. Seven adolescents were enrolled; mean age was 15.4 years, CD4 was 775 cells/mm 3 and all had HIV-RNA < 50 copies/ml. Proportions of adolescents with protective antiHBs were 86% at months 1 and 2, and 100% at month 3. Geometric means of antiHBs were 1.1 at baseline, 101.6 at 1 month, 137.1 at 2 months, and 355.9 mIU/ml at 3 months after the first DDHBVV. No grade 3-4 adverse event was reported. DDHBVV is an option for HIV-infected adolescents who are non-responder to standard HBVV revaccination. |
| first_indexed | 2024-12-14T03:41:55Z |
| format | Article |
| id | doaj.art-21edcf5507f140398eff197c4a1e3962 |
| institution | Directory Open Access Journal |
| issn | 2325-9574 2325-9582 |
| language | English |
| last_indexed | 2024-12-14T03:41:55Z |
| publishDate | 2013-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of the International Association of Providers of AIDS Care |
| spelling | doaj.art-21edcf5507f140398eff197c4a1e39622022-12-21T23:18:27ZengSAGE PublishingJournal of the International Association of Providers of AIDS Care2325-95742325-95822013-05-011210.1177/1545109712473651Double-Dose Hepatitis B Revaccination in Nonresponsive HIV-Infected AdolescentsTorsak Bunupuradah MD0Jintanat Ananworanich MD, PhD1Thanyawee Puthanakit MD2The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), the Thai Red Cross AIDS Research Centre, Bangkok, ThailandSEARCH, the Thai Red Cross AIDS Research Centre, Bangkok, ThailandDepartment of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandThere is no consensus regarding a best dosing regimen of hepatitis B virus vaccine (HBVV) for non-responsive HIV-infected individuals. Double-dose of hepatitis B vaccine (DDHBVV) could enhance immunogenicity to HBVV in non-responsive HIV-infected adults. We assessed the immunogenicity of DDHBVV in HIV-infected adolescents who failed to respond to standard HBVV revaccination. HIV-infected adolescents with current CD4 ≥ 200 cells/mm 3 and no protective antibody concentration of hepatitis B surface antibodies (antiHBs) after HBVV revaccination received DDHBVV, at months 0, 1, 2. The HBVV doses were 20 microgram per dose for adolescents aged < 18 years and 40 microgram per dose for adolescents aged ≥ 18 years. AntiHBs titers were measured at 1, 2, 3 months after first DDHBVV. AntiHBs ≥ 10 mIU/ml was considered protective. Seven adolescents were enrolled; mean age was 15.4 years, CD4 was 775 cells/mm 3 and all had HIV-RNA < 50 copies/ml. Proportions of adolescents with protective antiHBs were 86% at months 1 and 2, and 100% at month 3. Geometric means of antiHBs were 1.1 at baseline, 101.6 at 1 month, 137.1 at 2 months, and 355.9 mIU/ml at 3 months after the first DDHBVV. No grade 3-4 adverse event was reported. DDHBVV is an option for HIV-infected adolescents who are non-responder to standard HBVV revaccination.https://doi.org/10.1177/1545109712473651 |
| spellingShingle | Torsak Bunupuradah MD Jintanat Ananworanich MD, PhD Thanyawee Puthanakit MD Double-Dose Hepatitis B Revaccination in Nonresponsive HIV-Infected Adolescents Journal of the International Association of Providers of AIDS Care |
| title | Double-Dose Hepatitis B Revaccination in Nonresponsive HIV-Infected Adolescents |
| title_full | Double-Dose Hepatitis B Revaccination in Nonresponsive HIV-Infected Adolescents |
| title_fullStr | Double-Dose Hepatitis B Revaccination in Nonresponsive HIV-Infected Adolescents |
| title_full_unstemmed | Double-Dose Hepatitis B Revaccination in Nonresponsive HIV-Infected Adolescents |
| title_short | Double-Dose Hepatitis B Revaccination in Nonresponsive HIV-Infected Adolescents |
| title_sort | double dose hepatitis b revaccination in nonresponsive hiv infected adolescents |
| url | https://doi.org/10.1177/1545109712473651 |
| work_keys_str_mv | AT torsakbunupuradahmd doubledosehepatitisbrevaccinationinnonresponsivehivinfectedadolescents AT jintanatananworanichmdphd doubledosehepatitisbrevaccinationinnonresponsivehivinfectedadolescents AT thanyaweeputhanakitmd doubledosehepatitisbrevaccinationinnonresponsivehivinfectedadolescents |